Navigation Links
Onconase has Potential as Chemopreventive Agent in Mesothelioma,,Reports World-Renowned Mesothelioma Researcher at AACR Annual,Meeting

d. Previously, Dr. Carbone was Director of the Thoracic Oncology Program at Loyola University in Chicago, where he is also a tenured Professor at the Cancer Center, Department of Pathology. He also held scientific and academic positions at the National Institutes of Health (NIH), and at the University of Chicago.

Kuslima Shogen, Alfacell's chairman and chief executive officer, added: "Dr. Carbone is recognized as one of the world's leading researchers in mesothelioma. His remarks about ONCONASE at the AACR Annual Meeting reflect the interest of the international medical community in expanding the potential uses of ONCONASE."

About ONCONASE(R)

ONCONASE is a first-in-class therapeutic product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. ONCONASE triggers apoptosis, the natural death of cells, via multiple molecular mechanisms of action.

About Alfacell Corporation

Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of ONCONASE in non-small cell lung cancer (NSCLC) and other solid tumors. For more information, visit www.alfacell.com.

Safe Harbor

This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar ex
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Preclinical Data Show Alfacells Onconase Inhibits Tumor Growth of Non-Small Cell Lung Cancer, Breast Cancer Cells
2. Researchers Identify Intracellular Pathway of Alfacells Onconase
3. In vivo Study Results Demonstrating Potential of Alfacells Onconase for Treatment of Non-Small Cell Lung Cancer Published in Anticancer Research
4. Studies Show Mild Hyperthermia Enhances Antitumor Effects of Alfacells Onconase
5. Alfacells Onconase Highlighted in Latest Edition of Handbook of Therapeutic Antibodies
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. New Information on the Potential of Plasmin Shared at ISTH Congress
8. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
9. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
10. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
11. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
Post Your Comments:
(Date:11/26/2014)... THE WOODLANDS, Texas , Nov. 26, 2014 ... LXRX ) today announced the completion of previously ... of $280.0 million.  After fees and estimated offering ... million from the transactions.  The transactions consisted of: ... shares of common stock, pursuant to a registration ...
(Date:11/26/2014)... -- Investor-Edge has initiated coverage on the following ... PLC (NASDAQ: HZNP ), Endocyte Inc. (NASDAQ: ... ), and Theravance Inc. (NASDAQ: THRX ). Free ... http://investor-edge.com/register . On Tuesday, November 25, 2014, the ... Industrial Average edged 0.02% lower, to finish the day at ...
(Date:11/26/2014)... Zynerba Pharmaceuticals , Inc., a specialty ... synthetic cannabinoid treatments, today announced that the company will ... 2014. The conference will be held December 2 to ... New York . Zynerba,s Chairman and CEO, ... Tuesday, December 2. To listen to a ...
Breaking Medicine Technology:Lexicon Announces Completion Of $280 Million In Financing Transactions 2Lexicon Announces Completion Of $280 Million In Financing Transactions 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2
(Date:11/26/2014)... 26, 2014 (HealthDay News) -- New regulations to reduce ... and factories were issued Wednesday by the U.S. Environmental ... heart disease and premature death. The new rules ... 75 parts per billion to between 65 to 70 ... pollution standards in line with the latest science will ...
(Date:11/26/2014)... Steven Reinberg HealthDay Reporter ... American adults are smoking cigarettes than ever, health officials said. ... from about 21 percent in 2005 to 18 percent in ... 45.1 million to 42.1 million, despite the increasing population, according ... However,"we still have a long way to go, ...
(Date:11/26/2014)... The report “Laboratory Information System/LIS Market by Type ... User Labs (Clinical, Molecular Diagnostic, Blood Bank, Anatomic ... Forecast to 2019” provides a detailed overview of ... trends, and strategies impacting the LIS market along ... and market growth. , Browse 85 market data ...
(Date:11/26/2014)... The family foundation of Best Buy founder, Richard ... Foundation (Meso Foundation), half of which will be specifically ... Program . The focus area of the Richard M. ... organizations that can generate transformational results in education, human ... and chairman emeritus of Best Buy Co., Inc., the ...
(Date:11/26/2014)... Francisco, Claifornia (PRWEB) November 26, 2014 ... invasive procedures which include image guided surgeries has ... contrast media injectors. Rising incidence of various types ... to a proportionate increase in demand for these ... The growth of contrast media injectors market can ...
Breaking Medicine News(10 mins):Health News:EPA Issues Tougher Rules on Ozone Emissions 2Health News:EPA Issues Tougher Rules on Ozone Emissions 3Health News:U.S. Adult Smoking Rate Drops to New Low: CDC 2Health News:U.S. Adult Smoking Rate Drops to New Low: CDC 3Health News:Laboratory Information Systems Market by Type, Delivery Mode & End Users is Estimated to Reach $1,806.1 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Laboratory Information Systems Market by Type, Delivery Mode & End Users is Estimated to Reach $1,806.1 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Laboratory Information Systems Market by Type, Delivery Mode & End Users is Estimated to Reach $1,806.1 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Best Buy Founder’s Family Foundation Donates $100,000 to Organization Fighting Deadly Cancer 2Health News:Best Buy Founder’s Family Foundation Donates $100,000 to Organization Fighting Deadly Cancer 3Health News:Contrast Media Injectors Market To 2020 - Global Industry, Growth, Size, Share, Trends, Analysis And Forecast To 2020 Research Report By Grand View Research, Inc. 2Health News:Contrast Media Injectors Market To 2020 - Global Industry, Growth, Size, Share, Trends, Analysis And Forecast To 2020 Research Report By Grand View Research, Inc. 3
... residents,fortunate enough to be returning to intact homes ... fine airborne particulate matter and strong, lingering,smoke odor. ... the affected areas equip themselves,with tools that offer ... relief from smoke odor," says Sam Teitelbaum,President of ...
... (Nasdaq: GNTA ) announced today that Dr. ... Board of Directors. Dr.,McCaughey has served on the ... and health policy expert, we appreciate Betsy,s,commitment to ... resistant organisms, along with her increasing involvement in ...
... WHEATON, Ill., Oct. 26 The following is a,media ... Rehabilitation Hospital is the 2007 recipient of the,James Brady ... or organization,that goes above and beyond to improve lives ... goals of the Brain Injury Association of,Illinois., In ...
... Lynne Eldridge, M.D., author,of Avoiding Cancer One Day At a ... forms of cancer during a series of FREE seminars at,the ... downtown San Jose on,Sunday October 28th between 10am and 3pm. ... tech museum you can also visit the,amazing Body Worlds exhibit. ...
... be cut with more testing and early detection, , , ... American women think that if there,s no family history ... a new survey found. , In fact, most people ... according to the American College of Obstetricians and Gynecologists ...
... discuss third quarter financial results -, LAVAL, QC, ... today announced that it will host a conference call ... discuss its third quarter,2007 financial results. Labopharm will report ... approximately 7:00 a.m. the same day. To access ...
Cached Medicine News:Health News:In the Aftermath: Smoke Odor and Fine Particulate Matter a Serious Concern 2Health News:Genta Announces Resignation of Dr. Betsy McCaughey from Board of Directors 2Health News:Genta Announces Resignation of Dr. Betsy McCaughey from Board of Directors 3Health News:Marianjoy Rehabilitation Hospital to Receive James Brady Award From Brain Injury Association of Illinois 2Health News:Author Reveals How to Cancer Proof Your Life on October 28th 2Health News:Survey Finds Many Women Misinformed About Cancer 2Health News:Survey Finds Many Women Misinformed About Cancer 3Health News:Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET) 2
... testing feature single-well ANA screen and ENA ... tests including dsDNA, and 6 individual ENA ... Scl-70 and Jo-1. In addition, our autoimmune ... products for Cardiolipins (IgA, IgG, IgM), Thyroglobulin, ...
... autoimmune testing feature single-well ANA screen and ... reflex tests including dsDNA, and 6 individual ... (La), Scl-70 and Jo-1. In addition, our ... of products for Cardiolipins (IgA, IgG, IgM), ...
... testing feature single-well ANA screen and ENA ... tests including dsDNA, and 6 individual ENA ... Scl-70 and Jo-1. In addition, our autoimmune ... products for Cardiolipins (IgA, IgG, IgM), Thyroglobulin, ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: